Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab plus anlotinib in first-line unresectable HCC
NCT04172571Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Nov 2018
- Primary completion
- Jun 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of penpulimab, anlotinib in hepatocellular carcinoma (HCC), sponsored by Akeso, Inc.. Started Nov 2018; status: completed.
02
Drugs
penpulimabanlotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04172571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04172571.